Hjem › Eggstokkreft › Nebraska
Kliniske studier for Eggstokkreft i Nebraska
15 studier for Eggstokkreft søker deltakere på steder i Nebraska.
Byer i Nebraska
Offisiell studietekst (engelsk)
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- Nebraska Cancer Specialists, Omaha
- XCancer, Omaha
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT07189871A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
- University Of Nebraska Medical Center /ID# 281020, Omaha
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 30. sep. 2026 · NCT07278336First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
- University of Nebraska Medical Center, Omaha
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 29. sep. 2026 · NCT06799065A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- Nebraska Cancer Specialists, Omaha
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 17. sep. 2026 · NCT07109726A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- Nebraska Methodist Hospital ( Site 0004), Omaha
- University Of Nebraska Medical Center ( Site 0035), Omaha
RekruttererFase 3
Alder 18 og eldre · Kvinner · Oppdatert 17. sep. 2026 · NCT07318558A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Nebraska Methodist Hospital, Omaha
RekruttererFase 2
Alder 18 til 99 · Kvinner · Oppdatert 15. sep. 2026 · NCT07023627A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- Nebraska Methodist Hospital ( Site 0053), Omaha
RekruttererFase 3
Alder 18 og eldre · Kvinner · Oppdatert 3. sep. 2026 · NCT06824467Study of NTB-928 in R/R OC
- University of Nebraska Medical Center, Omaha
RekruttererFase 1
Alder 18 og eldre · Kvinner · Oppdatert 20. aug. 2026 · NCT07690189A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- Fred and Pamela Buffett Cancer Center - Kearney, Kearney
- Nebraska Cancer Specialists/Oncology Hematology West PC - MECC, Omaha
- Nebraska Methodist Hospital, Omaha
- og 2 flere
Rekrutterer
Alder 35 til 50 · Kvinner · Oppdatert 7. aug. 2026 · NCT04251052Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- Nebraska Medicine-Bellevue, Bellevue
- CHI Health Saint Francis, Grand Island
- Fred and Pamela Buffett Cancer Center - Kearney, Kearney
- og 8 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 7. aug. 2026 · NCT06580314A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Nebraska Cancer Specialists - Midwest Cancer Center - Legacy, Omaha
RekruttererFase 2
Alder 8 og eldre · Alle kjønn · Oppdatert 27. jul. 2026 · NCT05503797Lead-212 PSV359 Therapy for Patients With Solid Tumors
- Nebraska Cancer Specialists, Omaha
RekruttererFase 1/2
Alder 18 til 90 · Alle kjønn · Oppdatert 6. jul. 2026 · NCT06710756Integrated Cancer Repository for Cancer Research
- Mary Lanning Healthcare, Morrison Cancer Center, Hastings
- Faith Regional Health Services, Carson Cancer Center, Norfolk
- Great Plains Regional Medical Center, North Platte
- og 3 flere
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 19 til 110 · Alle kjønn · Oppdatert 29. jun. 2026 · NCT02012699DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- USA14-0, Lincoln
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 22. mai 2026 · NCT06953089SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Omaha
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 28. okt. 2025 · NCT03452774Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.